Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer-Reference-Cited by-同舟云学术

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Published:2021-08-25 Issue:23 Volume:27 Page:6413-6423
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Even Caroline,Wang Hung-Ming^ORCID,Li Shau-Hsuan,Ngan Roger K-C^ORCID,Dechaphunkul Arunee^ORCID,Zhang Li,Yen Chia-Jui,Chan Po Chung,Chakrabandhu Somvilai,Ma Brigette B.Y.,Tanasanvimon Suebpong^ORCID,Lee Victor H.F.^ORCID,Lou Pei-Jen,Li Zujun,Spira Alexander I.,Sukari Ammar,Guigay Joël,McCune Steven^ORCID,Gonzalez-Maffe Juan,Szpakowski Sebastian,Yao Yao^ORCID,Liang Hongzi,Mataraza Jennifer,Séchaud Romain,Manenti Luigi,Lim Darren W-T.^ORCID

Funder

Novartis

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12);OncoImmunology;2024-06-24

2. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma;npj Precision Oncology;2024-05-16

3. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis;Cancer Immunology, Immunotherapy;2024-05-11

4. Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study;Anticancer Research;2024-02-29

5. Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy;Clinical and Translational Oncology;2023-12-09